Sukmawati Dewi, Tanaka Rica
Department of Plastic and Reconstructive Surgery, Juntendo University School of Medicine Tokyo, Japan ; Department of Cardiovascular Medicine, Juntendo University School of Medicine Tokyo, Japan.
Department of Plastic and Reconstructive Surgery, Juntendo University School of Medicine Tokyo, Japan.
Am J Transl Res. 2015 Mar 15;7(3):411-21. eCollection 2015.
The concept of Endothelial Progenitor Cells (EPCs) therapy for adult neovascularization has continuously received attention. They are believed to participate in endothelial repair and post natal angiogenesis due to their abilities in differentiating into endothelial cells and producing protective cytokines and growth factors. Abundant evidence supports the involvement of EPCs in capillary growth and in participating in the formation of collateral vessels, which lead to improved vascular perfusion and functional recovery in target tissue. Autologous EPC now is becoming a novel treatment option for therapeutic revascularization and vascular repair in ischemic diseases. However, various diseases such as diabetes, heart disease and ischemic diseases are related to EPC dysfunction and give rise to additional challenges of autologous EPC therapy. A novel strategy to enhance the number and function of EPCs is needed to be established to provide successful autologous EPCs therapy. Currently, clinical trials for the new generation of EPC therapy in treating peripheral ischemic diseases are underway. In this review we provide an overview and the limitations of current EPCs therapy with an introduction to the new strategies of next generation EPC therapy for more promising vascular and tissue regeneration therapy.
内皮祖细胞（EPCs）疗法用于成人血管新生的概念一直备受关注。由于它们具有分化为内皮细胞以及产生保护性细胞因子和生长因子的能力，人们认为它们参与内皮修复和出生后的血管生成。大量证据支持EPCs参与毛细血管生长以及参与侧支血管的形成，这导致靶组织中血管灌注改善和功能恢复。自体EPCs目前正成为缺血性疾病中治疗性血管再生和血管修复的一种新的治疗选择。然而，诸如糖尿病、心脏病和缺血性疾病等各种疾病与EPC功能障碍有关，并给自体EPCs疗法带来了额外挑战。需要建立一种新策略来增加EPCs的数量并增强其功能，以提供成功的自体EPCs疗法。目前，新一代EPC疗法治疗外周缺血性疾病的临床试验正在进行中。在本综述中，我们概述了当前EPCs疗法及其局限性，并介绍了新一代EPC疗法的新策略，以期实现更有前景的血管和组织再生治疗。
